IBIO News & Events

"This last quarter was marked by significant advancement across our full pipeline. Most importantly, we received the clearance to enter the clinic with IBIO-600, which we believe has best-in-class potential due to its ability to preserve lean mass and improve body composition in obesity," said Martin Brenner, CEO and chief scientific officer of iBio. "We also presented new data for IBIO-610 demonstrating targeted reduction of total and visceral fat in obese non-human primates and expanded our pipeline with our selective bispecific antibody designed to block Activin A, GDF8 and GDF11, potentially to treat PH-HFpEF, which represents a high unmet need. Together, these milestones continue to demonstrate the significant potential of our platform and our commitment to developing differentiated therapies to meaningfully impact the lives of patients."

iBio announced IBIO-600 has received clinical trial notification acknowledgement from Australia's Therapeutic Goods Administration and ethics approval from a Human Research Ethics Committee, enabling the initiation of a first-in-human clinical trial of IBIO-600 in Australia. The Phase 1 study is a randomized, double-blind, placebo-controlled, single ascending dose trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IBIO-600 in overweight and obese adult participants. iBio expects to dose the first participant in the second quarter of 2026.